[Education] Breast Cancer Top 10 Clinical Pearls

HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.

 

These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.

 

In this episode of HOPA Now, Dr. Neelam Patel highlights various drug regimens and recommendations including adjuvant Anti-HER2 therapy, PIK3CA, characteristics of CDK4/6 inhibitors, and considerations for adjuvant chemotherapy. She details the key role that pharmacists can play in helping manage potential toxicities and ends with recommendations on when to stop therapy and how to employ supported care.

 

In this episode you will learn:

 

Breast Cancer Top 10 Clinical Pearls

• Utilizing adjuvant Anti-HER2 therapy based on residual disease versus no residual disease
• The relationship between PIK3CA and the place of Alpelisib in therapy
• Mechanical characteristics of CDK4/6 inhibitors, dosing recommendations, recent changes, and its place in therapy
• NCCN guidelines for using endocrine therapy versus cytotoxic therapy in metastatic breast cancer
• Adjuvant chemotherapy for hormone receptor-positive HER2-negative disease and findings of the TAILORx study
• PARP inhibitors used in treating breast cancers and adjuvant Capecitabine
• Bone modifying therapy and drug dosing recommendations
• The evaluation of metastatic disease, when to stop therapy, and supported care

 

Mentioned in This Episode:

HOPA

 

Tweetables:

 

“Ado-trastuzumab emtansine is recommended in the adjuvant setting if patients have residual disease following neoadjuvant HER2 targeted therapy.” — Dr. Neelam Patel

 

“Close monitoring and management is one of the key roles that we can play as pharmacists in helping manage these toxicities.” — Dr. Neelam Patel

 

“If a patient is symptomatic and requires quick disease control, cytotoxic chemotherapy may be recommended.” — Dr. Neelam Patel

 

“In general, chemotherapy is chosen based on patient-specific risk factors.” — Dr. Neelam Patel